Robert Huben
About
In The Last Decade
Robert Huben
12 papers receiving 484 citations
Peers
Comparison fields: 5 of 55
- Pulmonary and Respiratory Medicine 298
- Molecular Biology 206
- Cancer Research 149
- Oncology 95
- Surgery 78
Countries citing papers authored by Robert Huben
This map shows the geographic impact of Robert Huben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Huben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Huben more than expected).
Fields of papers citing papers by Robert Huben
This network shows the impact of papers produced by Robert Huben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Huben. The network helps show where Robert Huben may publish in the future.
Co-authorship network of co-authors of Robert Huben
This figure shows the co-authorship network connecting the top 25 collaborators of Robert Huben. A scholar is included among the top collaborators of Robert Huben based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Huben. Robert Huben is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 33 | |
| 2 | 13 | |
| 3 | 15 | |
| 4 | 97 | |
| 5 | Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer. | 43 |
| 6 | 13 | |
| 7 | 41 | |
| 8 | 2 | |
| 9 | 35 | |
| 10 | 22 | |
| 11 | Cytogenetic studies of tumor tissue from patients with nonfamilial renal cell carcinoma. | 148 |
| 12 | 44 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.